Search - tctmd.com

Displaying 421 - 440 of 628

Sort: Relevancy | Date

Presentation

Optimal Timing of an Invasive Strategy with NSTE ACS Patients

August 14, 2017

News Daily News

Early Invasive Strategy Benefits Select High-Risk NSTE ACS Patients, Meta-analysis Suggests

Michael O'Riordan

August 14, 2017

News Daily News

Staying on Statins After an Adverse Event Lowers Risks of Death, MI or Stroke

Michael O'Riordan

July 25, 2017

News Daily News

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

Leah Lawrence

July 24, 2017

News Daily News

More Vascular Complications, Higher 30-Day Mortality With PCI Prior to TAVR: Meta-Analysis

Michael O'Riordan

July 03, 2017

News Daily News

Aspirin Use by Elderly Patients After Vascular Events Linked to More Bleeding, Especially GI Bleeds

Michael O'Riordan

June 14, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2017

Shelley Wood

June 01, 2017

News Daily News

Beta-Blockers Questioned Anew in Post-MI Patients Without Heart Failure

L.A. McKeown

May 31, 2017

News Features

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

Michael O'Riordan

May 23, 2017

News Conference News EuroPCR 2017

Best Antiplatelet Therapy in Real-World PCI? European Registries Fuel the Debate

Caitlin E. Cox

May 22, 2017

News Daily News

Large US Study Suggests Little Difference Between Bivalirudin and Heparin for Transradial Primary PCI

Todd Neale

May 22, 2017

TOPIC: Replacing P2Y12 Inhibitors With Clopidogrel 1 Month After ACS Saves Money, Prevents Bleeding

News Conference News EuroPCR 2017

TOPIC: Replacing P2Y12 Inhibitors With Clopidogrel 1 Month After PCI Saves Money, Prevents Bleeding in ACS

Yael L. Maxwell

May 16, 2017

News Daily News

$2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor

Michael O'Riordan

May 12, 2017

News Daily News

Thirty-Day Readmission in Acute MI Not Linked With Hospital Care or Clinical Outcomes

Michael O'Riordan

April 27, 2017

News Daily News

Who Should Get a Statin? Guidelines Don’t Match Up

Michael O'Riordan

April 20, 2017

News Daily News

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Michael O'Riordan

April 04, 2017

News Conference News ACC 2017

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Michael O'Riordan

March 21, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Daily News

The Long and Short of It: DAPT Duration Choice After Stenting Gets Help From New Score

Todd Neale

March 10, 2017

News Daily News

Meta-analysis Calls Into Question Strength of Guidance for RAS Blockade in Patients With Stable CAD

Todd Neale

January 19, 2017

Advertisement

Optimal Timing of an Invasive Strategy with NSTE ACS Patients

Early Invasive Strategy Benefits Select High-Risk NSTE ACS Patients, Meta-analysis Suggests

Staying on Statins After an Adverse Event Lowers Risks of Death, MI or Stroke

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

More Vascular Complications, Higher 30-Day Mortality With PCI Prior to TAVR: Meta-Analysis

Aspirin Use by Elderly Patients After Vascular Events Linked to More Bleeding, Especially GI Bleeds

TCTMD’s Top 10 Most Popular Stories for May 2017

Beta-Blockers Questioned Anew in Post-MI Patients Without Heart Failure

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

Best Antiplatelet Therapy in Real-World PCI? European Registries Fuel the Debate

Large US Study Suggests Little Difference Between Bivalirudin and Heparin for Transradial Primary PCI

TOPIC: Replacing P2Y12 Inhibitors With Clopidogrel 1 Month After PCI Saves Money, Prevents Bleeding in ACS

$2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor

Thirty-Day Readmission in Acute MI Not Linked With Hospital Care or Clinical Outcomes

Who Should Get a Statin? Guidelines Don’t Match Up

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

The Long and Short of It: DAPT Duration Choice After Stenting Gets Help From New Score

Meta-analysis Calls Into Question Strength of Guidance for RAS Blockade in Patients With Stable CAD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content